RBC cuts Zscaler stock price target on sales leadership changes By Investing.com

Zscaler reported Q3 EPS of $1.08 and revenue of $850.48 million, both above consensus, but its FY2027 ARR and revenue growth outlook of 16%-17% came in below market expectations of 18.6% and 19.5%. RBC Capital trimmed its price target to $200 from $205, while Evercore ISI downgraded the stock to In Line and Morgan Stanley cut its target to $145 amid concerns over sales leadership turnover and SASE competition. The shares were cited at $184.60, down 27% over the past six months, despite strong 77% gross margins and continued organic ARR growth.

Analysis

ZS is signaling a classic “good quarter, weaker setup” transition: near-term execution still looks intact, but the market is now forced to discount a slower second derivative in billings/ARR just as cybersecurity multiple compression remains unresolved. The key second-order issue is not the guide itself, but leadership churn at the exact layer that drives logo acquisition and cross-sell velocity; that creates a 2-4 quarter digestion period where even stable demand can translate into missed operating leverage.

The more interesting read-through is competitive, not company-specific. If Zscaler’s growth re-sets to the mid-teens, buyers of SASE and zero-trust infrastructure will likely reallocate budget toward vendors with clearer sales continuity or broader platform bundling, pressuring standalone best-of-breed names while benefiting hyperscaler-adjacent security layers and larger suite vendors. In other words, this is less about market-size erosion and more about share path uncertainty, which tends to hit valuation before it hits revenue.

The move may be partially overdone on the downside because the starting point is still a high-quality business with strong gross margins and durable demand, so any evidence of salesforce stabilization could trigger a sharp multiple rebound. But absent proof that the new leadership can re-accelerate new-logo conversion by the next 1-2 quarters, the stock likely stays range-bound and vulnerable to estimate cuts. The real catalyst to watch is whether FY27 guidance proves a floor or a ceiling; if management can later frame the 16-17% range as conservatively baked with Mythos contribution plus salesforce rebuild, the name can re-rate quickly.

Key Decisions for Investors

• Short ZS on any post-earnings strength toward the consensus gap-fill zone; use a 3-6 month horizon and keep a tight stop above the pre-guidance multiple peak, because the stock likely trades on guidance credibility rather than current-quarter beat size.
• Pair trade: long MSFT or PANW vs short ZS for the next 1-2 quarters. The thesis is that platform/bundle vendors with broader budget capture should outperform a standalone name facing sales execution noise and a softer forward setup.
• If already long ZS, overwrite with 1-2 quarter covered calls to monetize elevated event risk while waiting for proof of salesforce stabilization; this keeps upside if the market decides the guide was conservative, but cushions another guidance-driven drawdown.
• For tactical longs, wait for a selloff and only buy once channel checks show new-logo conversion stabilizing; otherwise the risk/reward remains asymmetric to the downside for the next 60-90 days.
• Watch for any mention of pipeline conversion or rep hiring retention in the next print; if those metrics improve, cover shorts quickly, as a 10-15% multiple rebound is plausible even before ARR re-accelerates.